PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26084280-13	2015	CONCLUSIONS: PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by enhancing Bim expression via p38 activation.	Lapatinib	54-63	mitogen-activated protein kinase 14	Homo sapiens	134-137	
29387217-11	2018	In addition, lapatinib increased the levels of phospho-p38 MAPK and phospho-JNK, and decreased the levels of phospho-Akt.	Lapatinib	13-22	mitogen-activated protein kinase 14	Homo sapiens	55-58	
29387217-12	2018	The p38 inhibitor PD169316 partially blocked lapatinib-induced proliferation inhibition and apoptosis, whereas the JNK inhibitor SP600125 had no such effects.	Lapatinib	45-54	mitogen-activated protein kinase 14	Homo sapiens	4-7	
29154981-4	2018	Of these, p38 MAPK phosphorylation was confirmed to occur in response to inhibition of either EGFR or HER2 signaling through multiple validation steps, including differing bladder cancer cell lines (RT112, UM-UC-3, and T24) and methods of receptor pathway inhibition (erlotinib, lapatinib, and siRNA depletion of EGFR or HER2).	Lapatinib	279-288	mitogen-activated protein kinase 14	Homo sapiens	10-13	
26063481-7	2015	Western blot analysis revealed that lapatinib inhibited the phosphorylation of EGFR, AKT and p38 in doxorubicin-treated tumorspheres.	Lapatinib	36-45	mitogen-activated protein kinase 14	Homo sapiens	93-96	
26063481-10	2015	These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways.	Lapatinib	31-40	mitogen-activated protein kinase 14	Homo sapiens	176-179	
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	mitogen-activated protein kinase 14	Homo sapiens	225-233	
22219388-2	2012	Coadministration of lapatinib with obatoclax caused synergistic cell killing by eliciting autophagic cell death that was dependent upstream on mitochondrial reactive oxygen species generation and increased p62 levels and downstream on activation of p38 mitogen-activated protein kinase and inactivation of mammalian target of rapamycin.	Lapatinib	20-29	mitogen-activated protein kinase 14	Homo sapiens	249-252	
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	mitogen-activated protein kinase 14	Homo sapiens	172-180